➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,957,113

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,957,113 protect, and when does it expire?

Patent 8,957,113 protects LYSTEDA and is included in one NDA.

This patent has eight patent family members in two countries.

Summary for Patent: 8,957,113
Title:Tranexamic acid formulations
Abstract: Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.
Inventor(s): Moore; Keith A. (Loveland, OH), Heasley; Ralph A. (Webster Grove, MN), Greiwe; Jeffrey S. (Ft. Thomas, KY), Facemire; John W. (Douglasville, GA), Modest; Jason D. (Minneapolis, MN)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:13/016,800
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,957,113

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amring Pharms LYSTEDA tranexamic acid TABLET;ORAL 022430-001 Nov 13, 2009 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,957,113

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2008508275 ⤷  Free Forever Trial
Japan 2008508276 ⤷  Free Forever Trial
Japan 2011168596 ⤷  Free Forever Trial
Japan 2014193878 ⤷  Free Forever Trial
Japan 5000504 ⤷  Free Forever Trial
Japan 5205053 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2006023000 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.